🎯 Momentum #Options Activity trade ideas! Heavy institutional #optionsvolume far above daily averag

🎯 Momentum #Options Activity trade ideas! Heavy institutional #optionsvolume far above daily average with strong consensus on direction.

AM Algo #TradeIdea from 🔥 INSIDERFINANCE.COM 🔥
#BKKT, #TLS, #NEOG, #BW, #CGON

#OptionFlow #OptionsTrading #Trading

CG Oncology Reports 2025 Year End Financial Results and Provides Business Updates CG Oncology (NASDAQ: CGON) reported year-end 2025 results and pipeline timing updates on Feb 27, 2026. The company holds approximately $903.0 million in cash, cash equivalents and marketable securities as of Feb 26, 2026, expected to fund operations into the first half of 2029.Key clinical milestones include Phase 3 PIVOT-006 topline data and CORE-008 Cohort CX first combination results, both expected 1H 2026. 2025 operating metrics showed higher R&D and G&A spend and a wider net loss versus 2024.

#CGON CG Oncology Reports 2025 Year End Financial Results and Provides Business Updates

www.stocktitan.net/news/CGON/cg-oncology-re...

🚨 Institutions #optionsvolume surge detected! PM Top Momentum Activity from 🔥 INSIDERFINANCE.COM

🚨 Institutions #optionsvolume surge detected!

PM Top Momentum Activity from 🔥 INSIDERFINANCE.COM 🔥
1. #ARES 20.9x
2. #XEL 10.4x
3. #CGON 7.2x
4. #NVAX 7.0x
5. #PZZA 6.1x

#OptionFlow #OptionsTrading #Trading

🎯 Momentum #Options Activity trade ideas! Heavy institutional #optionsvolume far above daily averag

🎯 Momentum #Options Activity trade ideas! Heavy institutional #optionsvolume far above daily average with strong consensus on direction.

PM Algo #TradeIdea from 🔥 INSIDERFINANCE.COM 🔥
#XEL, #CGON, #NVAX, #PZZA, #PBR

#OptionFlow #OptionsTrading #Trading

🎯 Sweep Options Activity trade ideas! Institutions trading #options urgently with strong consensus

🎯 Sweep Options Activity trade ideas! Institutions trading #options urgently with strong consensus on direction.

PM Algo #TradeIdea from 🔥 INSIDERFINANCE.COM 🔥
#AMZN, #XEL, #CGON, #BE, #NVAX

#OptionFlow #OptionsTrading #Trading

New Cretostimogene Grenadenorepvec Data Highlight its Potential to Become the Backbone Therapy for High-Risk Non-Muscle Invasive Bladder Cancer CG Oncology (NASDAQ: CGON) reported topline results Dec 5, 2025 from BOND-003 Cohort P and CORE-008 Cohort A showing promising efficacy and tolerability for cretostimogene in non‑muscle invasive bladder cancer (NMIBC).In BOND-003 Cohort P (BCG‑unresponsive papillary-only), HG‑EFS by Kaplan‑Meier at 3/6/9 months was 95.7%, 84.6% and 80.4% (data cut-off Sep 1, 2025; 51 evaluable patients). CORE-008 Cohort A (high‑risk, BCG‑naïve CIS) showed overall CR 83.7% with optimized administration CR 88.0% (data cut-off Sep 1, 2025; 49 evaluable patients). No Grade ≥3 treatment‑related AEs, no treatment‑related discontinuations, and no progressions to MIBC reported.

#CGON New Cretostimogene Grenadenorepvec Data Highlight its Potential to Become the Backbone Therapy for High-Risk Non-Muscle Invasive Bladder Cancer

www.stocktitan.net/news/CGON/new-cretostimo...

CG Oncology Reports Third Quarter 2025 Financial Results and Provides Business Updates CG Oncology (NASDAQ: CGON) reported Q3 2025 results and business updates on Nov 14, 2025. Key clinical progress includes initiation of a rolling BLA submission for cretostimogene in high-risk BCG-unresponsive NMIBC with CIS, with completion expected in 2026, and a reported 24-month complete response (CR) rate of 41.8% (46/110) from BOND-003 Cohort C. The company completed enrollment of the Phase 3 PIVOT-006 trial ~10 months early and expects multiple topline readouts in 4Q'25–1H'26. Financially, cash and marketable securities were $680.3M as of Sept 30, 2025, projected to fund operations into H1 2028.

#CGON CG Oncology Reports Third Quarter 2025 Financial Results and Provides Business Updates

www.stocktitan.net/news/CGON/cg-oncology-re...

CG Oncology Continues to Demonstrate Best-in-Disease Durability and Tolerability in BOND-003 Cohort C; Additional 12 Patients in Complete Response at 24 Months CG Oncology (NASDAQ: CGON) has reported impressive updated data from its BOND-003 Cohort C trial for cretostimogene, showing a 41.8% complete response (CR) rate at 24 months in patients with high-risk non-muscle invasive bladder cancer (NMIBC) unresponsive to BCG treatment.The study demonstrated remarkable durability with 90% of 12-month responders remaining disease-free at 24 months. Among 110 heavily pretreated patients, 96.6% remained free from progression to muscle invasive disease at 24 months. The treatment showed excellent tolerability with no Grade 3 or greater treatment-related adverse events.The company plans to initiate its BLA submission for cretostimogene in Q4 2025, positioning it as a potential breakthrough bladder-sparing therapeutic option.

#CGON CG Oncology Continues to Demonstrate Best-in-Disease Durability and Tolerability in BOND-003 Cohort C; Additional 12 Patients in Complete Response at 24 Months

www.stocktitan.net/news/CGON/cg-oncology-co...

CG Oncology Completes Enrollment in PIVOT-006 – Rapid enrollment underscores high unmet need in intermediate-risk non-muscle invasive bladder cancer (NMIBC) – – One of the largest randomized phase 3 studies in this patient population will encompass broadest range of patient types per AUA/SUO Guidelines – IRVINE, Calif., Sept. 03, 2025 (GLOBE

#CGON CG Oncology Completes Enrollment in PIVOT-006

www.stocktitan.net/news/CGON/cg-oncology-co...

Cg Oncology (CGON) Q2 Loss Widens 93% | The Motley Fool

#CGON #eee915c1-30de-46f9-b2e8-1db76691d459 #data-news

Origin | Interest | Match

CG Oncology Achieves Best-in-Disease 75.5% Response Rate for Bladder Cancer Treatment, Plans Q4 BLA Filing Q2 results reveal breakthrough bladder cancer treatment data, $661M cash position, and favorable legal verdict. Key milestones ahead - Get full insights.

#CGON CG Oncology Reports Second Quarter 2025 Financial Results and Provides Business Updates

www.stocktitan.net/news/CGON/cg-oncology-re...

SmCpStr Technicals – Technical Indicators for Small-cap Stocks

Small-cap stocks with bearish moving average convergence divergence crossovers, Wed May 14th - #YQ #WBTN #USAU #SAIH #RIGL #PAMT #MBX #KNSA #HCSG #GANX #CGON #AFYA #SVV #HGVC #GETY - More: crystalequityresearch.com/SmCpStr/ - #smallcap

CG Oncology Reports First Quarter 2025 Financial Results and Provides Business Updates CG Oncology (NASDAQ: CGON) reported its Q1 2025 financial results and clinical progress. The company presented promising BOND-003 trial results showing 42.3% complete response rate at 24 months for Cohort C and 90.5% high-grade recurrence-free survival at 3 and 9 months for Cohort P in bladder cancer treatment. The company initiated CORE-008 Cohort CX trial evaluating cretostimogene with gemcitabine. Financially, CGON reported cash position of $688.4M, expected to fund operations into H1 2028. Q1 2025 saw increased expenses with R&D at $27.5M (up from $17.2M) and G&A at $14.8M (up from $5.8M), resulting in a net loss of $34.5M ($0.45 per share). Key upcoming milestones include BLA submission initiation and completion of PIVOT-006 Phase 3 enrollment in H2 2025.

#CGON CG Oncology Reports First Quarter 2025 Financial Results and Provides Business Updates

www.stocktitan.net/news/CGON/cg-oncology-re...

CG Oncology's Bladder Cancer Drug Shows 75.5% Success Rate as Cash Reserves Hit $742M Latest data reveals breakthrough 75.5% response rate in bladder cancer therapy, while $238M offering extends runway to 2028. See complete financial analysis inside.

#CGON CG Oncology Reports 2024 Year End Financial Results and Provides Business Updates

www.stocktitan.net/news/CGON/cg-oncology-re...

Breakthrough: Novel Bladder Cancer Drug Shows 75% Response Rate with 28-Month Durability Latest Phase 3 results reveal exceptional 75.5% complete response in BCG-resistant bladder cancer, with unprecedented 28-month durability. See full efficacy analysis.

#CGON Cretostimogene Grenadenorepvec Data Continues to Demonstrate Best-in-Class Durability of Response as well as Consistent and Compelling Safety and Efficacy

www.stocktitan.net/news/CGON/cretostimogene...

CG Oncology Launches Major $204M IPO with Shares Priced at $28, Backed by Top Wall Street Banks CG Oncology sets ambitious market entry with 8M share offering at $28 each, securing important funding for growth. Major investment banks lead this significant biotech IPO.

#CGON CG Oncology Announces Pricing of Public Offering

www.stocktitan.net/news/CGON/cg-oncology-an...

CG Oncology Launches Major 8M Share Public Offering, Backed by Top Wall Street Banks Leading bladder cancer therapeutics firm CG Oncology announces substantial public offering with Morgan Stanley and Goldman Sachs backing. Key details on share structure and timing.

#CGON CG Oncology Announces Proposed Public Offering

#offering #investing #StockMarket

www.stocktitan.net/news/CGON/cg-oncology-an...

CG Oncology Launches Groundbreaking Research Fellowship for Bladder Cancer Innovation | CGON Stock News SUO-CTC and CG Oncology introduce a pioneering fellowship program to advance Non-Muscle Invasive Bladder Cancer research, offering support for breakthrough treatments.

#CGON SUO-CTC and CG Oncology Announce the First Annual Non-Muscle Invasive Bladder Cancer (NMIBC) Research Fellowship Award

#cancer #investing #stocks

www.stocktitan.net/news/CGON/suo-ctc-and-cg...

#CGON CG Oncology to Present Results on Cretostimogene Grenadenorepvec at the Society of Urologic Oncology (SUO) 25th Annual Meeting

www.stocktitan.net/news/CGON/cg-oncology-to...